Ceronapril

Ceronapril
Clinical data
AHFS/Drugs.com	Monograph
ATC code	C09AA09 (WHO) ;
Identifiers
	IUPAC name 1-[(2S)-6-Amino-2-hydroxyhexanoyl]-L-proline, hydrogen (4-phenyl-butyl)phosphonate;
CAS Number	111223-26-8;
PubChem CID	189729;
ChemSpider	164789;
UNII	X3MM60SOVP;
KEGG	D03440;
CompTox Dashboard (EPA)	DTXSID80891418 ;
Chemical and physical data
Formula	C30H46NO7P
Molar mass	563.672 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H](N(C1)C(=O)[C@H](CCCCN)OP(=O)(CCCCC2=CC=CC=C2)O)C(=O)O;
	InChI InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39-/m1/s1 ; Key:BIDNLKIUORFRQP-YYTCENNOSA-N ;

Ceronapril (INN,[1] proposed trade names Ceranapril, Novopril) in a phosphonate ACE inhibitor[2] that was never marketed.

References

"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 31" (PDF). World Health Organization. p. 4. Retrieved 2 March 2017.
Tu JI, Brennan J, Stouffer B, Mantha S, Turabi N, Tsay HM (June 1992). "Radioimmunoassay for ceronapril, a new angiotensin-converting enzyme inhibitor, and its application to a pharmacokinetic study in healthy male volunteers". Therapeutic Drug Monitoring. 14 (3): 209–19. doi:10.1097/00007691-199206000-00007. PMID 1412607. S2CID 23854785.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril Dicarboxylate-containing: Enalapril^# Benazepril Cilazapril Delapril Imidapril Lisinopril (+HCT) Moexipril Perindopril (+indapamide) Quinapril (+HCT) Ramipril Spirapril Temocapril Trandolapril Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan Eprosartan Fimasartan Irbesartan (+HCT) Losartan (+HCT) Olmesartan (+amlodipine, +amlodipine and HCT) Tasosartan^§ Telmisartan (+amlodipine, +HCT) Valsartan (+amlodipine, +HCT)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III